Myland Inc recognizing there were limited options to their EpiPen, increased the price of EpiPen by approximately 400 percent and paid a fixed 13 percent rebate to Medicaid during the same period based on EpiPen's misclassification as a generic drug. underpaid rebates owed under the Medicaid Drug Rebate Program by erroneously classifying its patented, brand-name drug EpiPen - which has no therapeutic equivalents or generic competition - as a generic drug to avoid its obligation to pay higher rebates. Is this a False Claim violation?